COMPANY PRESENTATION February 2016 NASDAQ: KMDA
Company Snapshot Fully integrated, international (NASDAQ-traded) Strategic partnerships with industry leaders biopharmaceutical company (Inc. Baxalta, Biotest, Kedrion, Chiesi) Focused on Respiratory, orphan diseases and Exclusive distributer of plasma derived leading biopharmaceutical therapeutics companies with significant market share ( > 50%). Global leader for Alpha-1 Antitrypsin (AAT) Diversified portfolio with over 20 specialty products.
Mission Development, production and marketing of specialty, life-saving pharmaceuticals Strategy Unique Strategic Significant Product Line Partnerships Market Share 3
Media Coverage Bloomberg 11 Dec. 2014 11 Dec. 2013 2 Feb. 2015 Kamada Announces Completion Kamada Reports Encouraging Kamada Announces Positive of Pivotal Phase ll/lll Clinical Interim Data from its Phase Interim Results from Phase Trial in Europe and Canada of 1/2 Extension Study: AAT in I/II Clinical Study of its human inhaled AAT to Treat Alpha-1 pediatric patients with Type 1 Alpha-1 Antitrypsin to Treat Diabetes Graft-versus-Host Disease Antitrypsin Deficiency 24 Aug. 2010 31 May. 2013 4 Aug. 2012 Kamada and Baxter Enter into Kamada Ltd Announces New NASDAQ Welcomes a Strategic Agreement for the Exclusive Distribution Kamada Ltd. [KMDA] to Distribution and Manufacture Agreement with Chiesi The NASDAQ Stock of Intravenous Liquid AAT to Farmaceutici Market Treat Alpha-1 Antitrypsin Deficiency in the US 4
Multi-National Sales Platform Additional 10 countries in registration 5
Key Strategic Alliances
Diversified Product Portfolio Alpha-1 Antitrypsin I.V (human) RESPIRATORY Tobramycin Inhaled Beclomethasone+Formoterol Anti-rabies immunoglobulin (human) Rho(D) immunoglobulin (human) Rho(D) immunoglobulin (human) Gamma globulins (IgG) (human) ANTIBODIES Varicella zoster immunoglobulin (various expertise) Hepatitis B immunoglobulin (human) Hepatitis B immunoglobulin (human) CMV immunoglobulin (human) Anti-snake venom Heparin sodium 5,000 IU/ml Human serum Albumin CRITICAL AND Heparin sodium HOSPITAL CARE Bupivacaine HCl Coagulation Factor VIII (human) HAEMOPHILIA Coagulation Factor IX (human) 7
Clinical Pipeline Focused on Orphan Indications Product Indication Phase I Phase II Phase III Market Partner Intravenous AAT Deficiency U.S. FDA Approved (2010) AAT Ph II/III In Process D1-AAT (IV) Type 1 Diabetes* Completed U.S. G1-AAT (IV) GVHD* Ph I/II In Process U.S. L1-AAT (IV) Lung Transplant U.S. Ph I/II in Initiation EU : Completed EU Inhaled AAT AAT Deficiency* U.S .: Ph II In Process B1-AAT (IH) Bronchiectasis* Completed Completed C1-AAT (IH) Cystic Fibrosis* U.S .: IND Approved KamRAB (IM) Prophylaxis for U.S : Phase III Completed (LPO) U.S. Rabies * Orphan Drug Designation IV= intravenous IH= inhaled
Our Israeli Sales & Marketing Strengths & Capabilities Vast experience in various medical fields : Respiratory, cGMP standard, one stop shop: Allergy & Immunology, Hematology, Infectious diseases, registration, regulation support, importation, Neurology, Critical care, Gastroenterology & Liver distribution, storage, marketing, pharmacovigilance, diseases, Fertility and more. clinical trials and QA, QC. Proven multinational sales capabilities through long-term Long term experience in development and connection with local distributors in Latin America, CIS & marketing of specialty Rx pharmaceuticals. Asia. Excellent relationships with key personnel at the FDA approved , State of the art production facility. Israeli MOH and HMOs (management, decision makers, medical department and purchase More than 50% market share in key in-licensed products. department). 9
Dedicated to Create a Leading Brand Kamada’s success and market share growth is achieved through a collaboration with KOLs and the establishment of a leading premium brand. • A seasoned team of medical reps covering all hospitals and most primary-care clinics. • On going personal contact with KOLs and physicians. • Local adaptations of all marketing aids: leaflets, brochures, scientific articles, etc. • Sponsorship of relevant medical conferences & seminars. • Strong marketing intelligence capabilities. • Advanced digital marketing capabilities. • In-house medical director support. 10
Expertise in Market Development of Orphan Indications Patients and physicians organizations Market research & analysis, including support, Development of patients detailed business plan. support programs. Collaboration with KOLs and dedicated Experience in Named-Patient-Basis treatment centers. sales, prior to registration. Raising disease awareness & patients diagnosis, through effective diagnosis programs. 11
One-Stop-Shop Services • Regulatory Capabilities: o In-house, experienced dedicated regulatory affairs department. o Proven record in submission and approvals to the National health basket. o Pharmacovigilance (in cooperation with QA and Clinical). • Logistic Capabilities: o In-house storage (fully cGMP and FDA approved). o Extensive cold-chain expertise. o Advanced nation-wide cGDP-approved delivery platform. o Home care experience and capabilities. o Dedicated account management & customer service. 12
Novolog: Our Logistic Partner • The national leader in logistics for the pharmaceutical industry, with Cutting edge facility for the storage and distribution of pharmaceutical products • Serves more than 1,200 delivery points throughout Israel • Immediate life saving deliveries 24/7 13
A one- stop- shop strategic partner Unique expertise In-house seasoned through the entire Why Partner sales & marketing supply chain of with Kamada team specialty life- saving pharmaceuticals Multinational capabilities and strong financial positioning 14
THANK YOU Hanni Neheman | Director Sales & Marketing | hannin@kamada.com www.kamada.com 15
Recommend
More recommend
